If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Monday broker round-up

Mon, 11th May 2020 13:48
(Sharecast News) - Diploma: Peel Hunt downgrades to hold with a target price of 1,650p.

ITV: Berenberg reiterates hold with a target price of 88p.

Alpha Financial Markets Consulting: Berenberg reiterates buy with a target price of 190p.

Ncondezi Energy: Canaccord reiterates speculative buy with a target price of 13p.

Spire Healthcare: RBC Capital Markets downgrades to sector perform with a target price of 100p.

Superdry: RBC Capital Markets reiterates outperform with a target price of 250p.

Rolls-Royce: JP Morgan reiterates underweight with a target price of 155p.

Rio Tinto: JP Morgan reiterates neutral with a target price of 4,560p.

IMI: Deutsche Bank reiterates buy with a target price of 1,040p.

Sage Group: Deutsche Bank reiterates sell with a target price of 580p.

Rathbone Brothers: Liberum reiterates hold with a target price of 1,520p.

AstraZeneca: Liberum reiterates buy with a target price of 9,030p.

Dignity: Peel Hunt reiterates sell with a target price of 150p.

easyJet: Credit Suisse reiterates outperform with a target price of 746p. Astrazeneca Rio Tinto Sage Group Diploma Rathbone Spire Healthcare easyJet ITV IMI Rolls-Royce

Shares in this article

Related News

WINNERS & LOSERS: Astra down on failed test; Computacenter ups outlook
52 mins ago

WINNERS & LOSERS: Astra down on failed test; Computacenter ups outlook

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Thursday.

AstraZeneca shares slide after Ionis-partnered drug fails key heart disease trial
53 mins ago

AstraZeneca shares slide after Ionis-partnered drug fails key heart disease trial

* Wainua showed no effect in patients on stabilizer therapy

AstraZeneca shares slide on failure of cardiomyopathy trial
1 hour ago

AstraZeneca shares slide on failure of cardiomyopathy trial

(Sharecast News) - AstraZeneca said on Thursday that the phase 3 CARDIO-TTRansform trial of Wainua in adults with transthyretin-mediated amyloid cardi...